AIV007

AiViva BioPharma, Inc. · Phase 1 active Small molecule

At a glance

Generic name	AIV007
Sponsor	AiViva BioPharma, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) (PHASE1)
Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AIV007 CI brief — competitive landscape report
AIV007 updates RSS · CI watch RSS
AiViva BioPharma, Inc. portfolio CI